Literature DB >> 11702132

Spiral CT of the neck: When do neck malignancies delineate best during contrast enhancement?

M Keberle1, A Tschammler, K Berning, D Hahn.   

Abstract

The aim of this study was to determine the time of best contrast of neck malignancies in contrast-enhanced CT. The CT was done in 20 patients with squamous cell carcinoma using a standard protocol (100 ml contrast agent at 2 ml/s). Dynamic series of the tumors were performed (scan interval 6 s). In all relevant structures of the neck, densities were measured to obtain time-density curves. The best tumor contrast was measured > or =50 s after the start of the injection, and the best contrast of lymph nodes < or =75 s. For staging and volume measurements of neck primaries the best achievable contrast is necessary. Using the examined single-bolus technique, spiral CT allows a combination of perfect tumor contrast with a good contrast between lymph nodes and neck vessels between 50 and 75 s after starting the injection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11702132     DOI: 10.1007/s003300100859

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  3 in total

1.  Computed tomography angiography versus digital subtraction angiography in vascular mapping for planning of microsurgical reconstruction of the mandible.

Authors:  Michael Lell; Bernd F Tomandl; Katharina Anders; Ulrich Baum; Emeka Nkenke
Journal:  Eur Radiol       Date:  2005-04-27       Impact factor: 5.315

Review 2.  Computerised tomography and magnetic resonance imaging of laryngeal squamous cell carcinoma: A practical approach.

Authors:  Francesco Agnello; Francesco Cupido; Gianvincenzo Sparacia; Federico Midiri; Martina Miroddi; Emanuele Grassedonio; Massimo Galia
Journal:  Neuroradiol J       Date:  2017-02-20

3.  CT determination of lymphocytic infiltration around head and neck squamous cell carcinomas may be a predictor of lymph node metastases.

Authors:  Marc Keberle; Philipp Ströbel; Alexander Marx; Dietbert Hahn; Florian Hoppe
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-06-26       Impact factor: 2.503

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.